The Results of Serum Markers of Liver Fibrosis in Patients with Posthepatic Fibrosis and in Patients with Non-alcoholic Fatty Liver Disease Depending on Body Weight

This article observes the main trends in the diagnosis of non-alcoholic hepatic steatosis, which have been observed in world practice recently. From a practical point of view, one of the most significant events was the introduction of a new term “metabolically associated fatty liver disease” (MAFLD), which partly replaced the previously used term “primary non-alcoholic fatty liver disease”. The new nomenclature induces clear diagnostic criteria for MAFLD, and this disease has ceased to be a diagnosis of exclusion, as a result. In the near future, the practical aspects of the application of this nomenclature and new diagnostic criteria are to be evaluated. The second important trend is the increasing role of direct serum markers of liver fibrosis in the diagnosis and prognosis of MAFLD. Thus, collagen type 3 propeptide (PRO-C3), as well as M2BPGi (Mac2 Binding Proteine Glycosylation isomer), look very promising, since research data have demonstrated a higher diagnostic value of these markers in comparison with indirect fibrosis indices, which are most often used in clinical practice. In addition, the search continues for new direct serum markers of fibrosis, which would be more sensitive for detecting liver fibrosis of stages 1-2. In general, one should expect a gradual replacement by serological markers of fibrosis of technically more complex and expensive diagnostic methods, such as magnetic resonance elastography and fibroelastometry.

Download Full-text

Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.

Acta Biochimica Polonica ◽

10.18388/abp.2011_2225 ◽

2011 ◽

Vol 58 (4) ◽

Cited By ~ 31

Author(s):

Dariusz M Lebensztejn ◽

Aldona Wierzbicka ◽

Piotr Socha ◽

Maciej Pronicki ◽

Elżbieta Skiba ◽

...

Keyword(s):

Hyaluronic Acid ◽

Liver Disease ◽

Liver Fibrosis ◽

Liver Biopsy ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Serum Markers ◽

Cytokeratin 18 ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

There is a need to replace liver biopsy with non-invasive markers that predict the degree of liver fibrosis in fatty liver disease related to obesity. Therefore, we studied four potential serum markers of liver fibrosis and compared them with histopathological findings in liver biopsy in children with non-alcoholic fatty liver disease (NAFLD). We determined fasting serum level of hyaluronic acid (HA), laminin, YKL-40 and cytokeratin-18 M30 in 52 children (age range 4-19, mean 12 years, 80 % of them were overweight or obese) with biopsy-verified NAFLD. Viral hepatitis, autoimmune and metabolic liver diseases (Wilson's disease, alpha-1-antitrypsin deficiency, cystic fibrosis) were excluded. Fibrosis stage was assessed in a blinded fashion by one pathologist according to Kleiner. Receiver operating characteristics (ROC) analysis was used to calculate the power of the assays to detect liver fibrosis (AccuROC, Canada). Liver fibrosis was diagnosed in 19 children (37 %). The levels of HA and CK18M30 were significantly higher in children with fibrosis compared to children without fibrosis (p=0.04 and 0.05 respectively). The ability of serum HA (cut-off 19.1 ng/ml, Se=84 %, Sp=55 %, PPV=52 %, NPV=86 %) and CK18M30 (cut-off 210 u/l, Se=79 %, Sp=60 %, PPV=56 %, NPV=82 %) to differentiate children with fibrosis from those without fibrosis was significant (AUC=0.672 and 0.666, respectively). The combination of both markers was superior (AUC=0.73, p=0.002). Laminin and YKL-40 levels did not allow a useful prediction. Cytokeratin-18 and hyaluronic acid are suitable serum markers predicting liver fibrosis in children with NAFLD. Studying these markers may identify patients at risk of disease progression.

Download Full-text

Healthy PNPLA3 Risk Allele Carriers Present with Unexpected Body Fat Composition. A Study of One ousand Subjects

Journal of Gastrointestinal and Liver Diseases ◽

10.15403/jgld-1276 ◽

2014 ◽

Vol 23 (1) ◽

pp. 33-37 ◽

Cited By ~ 2

Author(s):

Agnieszka Kempinska-Podhorodecka ◽

Marcin Krawczyk ◽

Marta Klak ◽

Malgorzata Blatkiewicz ◽

Frank Lammert ◽

...

Keyword(s):

Body Weight ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

The Metabolic Syndrome ◽

Anthropometric Characteristics ◽

The Common ◽

Total Fat ◽

Alcoholic Fatty Liver Disease

Introduction: The common PNPLA3 (adiponutrin) variant p.I148M represents a major genetic driver of progression in non-alcoholic fatty liver disease (NAFLD). NAFLD is commonly associated with traits of the metabolic syndrome, therefore it is mostly suspected in obese individuals. Here, we investigate the association between the PNPLA3 variant and anthropometric traits in a cohort of healthy individuals.Patients and methods: We recruited 1,000 (500 females; age 18 - 66 years) healthy blood donors. The PNPLA3 variant was genotyped using TaqMan assays. All individuals were phenotyped with respect to anthropometric characteristics. We also determined the percentage of total fat (F%) and active tissue (TA%) of body weight.Results: Healthy carriers of the PNPLA3 [IM] and [MM] genotypes, although not differing in height from individuals with the genotype [II], displayed significantly lower body weight and lower BMI (both P = 0.005), higher TA% (P = 0.03) but lower F% (P = 0.03) and smaller waist, chest and shin circumferences (all P < 0.05). Separate analysis for males and females demonstrated an association between the [IM] and [MM] genotypes and higher TA% but lower F% (P = 0.04) in females. In males, BMI and total weight were significantly (P = 0.04) lower among carriers of the [M] allele.Discussion: Healthy individuals carrying the prosteatotic PNPLA3 allele p.I48M may be leaner as compared to the carriers of the common allele. Hence in clinical practice they might be overlooked since they do not necessarily present with the anthropometric characteristics commonly associated with severe hepatic steatosis.Abbreviations: ATX - autotaxin; BMI - body mass index; F% - total fat of body weight in %; Fkg - total fat of body weight in kilograms; GWAS - genome-wide association study; LPA - lysophosphatidic acid; NAFLD, non-alcoholic fatty liver disease; NASH - non-alcoholic steatohepatitis; PA - phosphatidic acid; PNPLA3-patatin-like phospholipase domain containing 3 (adiponutrin); TA% - active tissue of body weight in %; TAkg - active tissue of body weight in kilograms; WHR - waist-to-hip ratio.

Download Full-text

Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease

Choonpa Igaku ◽

10.3179/jjmu.jjmu.k.20 ◽

2020 ◽

Vol 47 (6) ◽

pp. 241-248

Author(s):

Hirohito TAKEUCHI ◽

Katsutoshi SUGIMOTO ◽

Hisashi OSHIRO ◽

Kunio IWATSUKA ◽

Shin KONO ◽

...

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Supersonic Shear Imaging ◽

Noninvasive Assessment ◽

Alcoholic Fatty Liver Disease

Download Full-text

Sarcopenia is associated with advanced liver fibrosis in patients with non-alcoholic fatty liver disease

Journal of Hepatology ◽

10.1016/s0168-8278(18)31952-4 ◽

2018 ◽

Vol 68 ◽

pp. S838

Author(s):

J.G. Park ◽

M.K. Kang ◽

J.H. Baek ◽

S.Y. Park ◽

H.J. Lee ◽

...

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Advanced Liver Fibrosis ◽

Alcoholic Fatty Liver Disease

Download Full-text

(-)-Epigallocatechin-3-gallate and atorvastatin treatment down-regulates liver fibrosis-related genes in non-alcoholic fatty liver disease

Clinical and Experimental Pharmacology and Physiology ◽

10.1111/1440-1681.12844 ◽

2017 ◽

Vol 44 (12) ◽

pp. 1180-1191 ◽

Cited By ~ 7

Author(s):

Le Ying ◽

Feng Yan ◽

Yueling Zhao ◽

Hugh Gao ◽

Bryan RG Williams ◽

...

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Atorvastatin Treatment ◽

Alcoholic Fatty Liver Disease

Download Full-text

Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with non‐alcoholic fatty liver disease

Hepatology Research ◽

10.1111/hepr.13282 ◽

2018 ◽

Vol 49 (3) ◽

pp. 296-303 ◽

Cited By ~ 7

Author(s):

Kenichi Tanaka ◽

Hirokazu Takahashi ◽

Hideyuki Hyogo ◽

Masafumi Ono ◽

Noriko Oza ◽

...

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

General Population ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Hemoglobin A1c ◽

Epidemiological Survey ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Download Full-text

Correlation Between Point Shear Wave Elastography and Liver Function Tests as A Predictor of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

10.53350/pjmhs211571936 ◽

2021 ◽

Vol 15 (7) ◽

pp. 1936-1939

Author(s):

Shahla Mohammed Saeed Rasul ◽

Ali Khalaf Salim ◽

Hiwa Abubakr Hussein

Keyword(s):

Liver Disease ◽

Liver Fibrosis ◽

Liver Function ◽

Fatty Liver ◽

Shear Wave ◽

Fatty Liver Disease ◽

Liver Function Tests ◽

Fibrosis Score ◽

Alcoholic Fatty Liver ◽

Alcoholic Fatty Liver Disease

Background: Nowadays, generating shear waves and simulation of the liver tissue is done using point shear-wave elastographic (pSWE) techniques which uess acoustic radiation force impulse (ARFI). Objective: This study aimed to evaluate the correlation between pSWE and liver function tests (LFTs) to predict liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Materials and methods: It was a cross sectional study conducted in an Ultrasound Clinic in Suleymaniya city. The duration of the study was from 1st of November, 2018 to 30th of June, 2019 which conducted on 50 NAFLD patients. After confirming NAFLD diagnosis, the patients were referred to Ultrasound Clinic to go under pSWE test. Results: The data showed that the mean PSWE of NAFLD patient was 4.12±0.87 Kpa; and 18% of them had high PSWE (> 4.6). Elastography fibrosis score was distributed to F0 (82%), F1 (6%), F2 (8%) and F3 (4%). There was a significant association between high APRI and high Aspartate Aminotransferase/Alanine Aminotransferase(AST/ALT) ratio (p=0.04). There was also a highly significant association between elastography fibrosis score and APRI fibrosis score among NAFLD patients (p<0.001). Conclusion: This study showed that the pSWE is a valuable noninvasive diagnostic technique for predicting liver fibrosis among NAFLD patients and there is significant correlation between APRI and pSWE scores. Keywords: Non-alcoholic fatty liver disease, Point shears wave elastography, Liver fibrosis.

Download Full-text

Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial

Nutrients ◽

10.3390/nu12113372 ◽

2020 ◽

Vol 12 (11) ◽

pp. 3372

Author(s):

Kátia Cansanção ◽

Marta Citelli ◽

Nathalie Carvalho Leite ◽

María-Carmen López de las Hazas ◽

Alberto Dávalos ◽

...

Keyword(s):

Fatty Acids ◽

Liver Disease ◽

Liver Fibrosis ◽

Fatty Liver ◽

Fish Oil ◽

Fatty Liver Disease ◽

Double Blind ◽

Alcoholic Fatty Liver ◽

Pufa Supplementation ◽

Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a chronic disease affecting up to 25% of the population worldwide. n-3 long-chain polyunsaturated fatty acids (n-3 PUFA) have been associated with improved clinical parameters of NAFLD. Our purpose was to conduct a pilot study to evaluate the effects of n-3 PUFA supplementation in a randomized, double-blind, placebo-controlled clinical study performed on NAFLD individuals diagnosed by ultrasound. Patients received n-3 PUFA (n = 13) or placebo (n = 11) supplementation for six months. Circulating miR-122 expression (determined by quantitative real time-polymerase chain reaction (qRT-PCR), liver fibrosis (FibroScan®), red blood cells (RBC) fatty acids (gas chromatography), and biochemical tests were performed at baseline and after intervention. After the intervention, in the n-3 PUFA group, docosahexaenoic acid (DHA) and omega index increased significantly in RBC (p = 0.022 and p = 0.012, respectively), in addition to a significant reduction in alkaline phosphatase (ALP) (p = 0.002) and liver fibrosis (p = 0.039). However, there was no change in the expression of circulating miR-122 in both groups. Our results showed that omega-3 PUFA were incorporated in erythrocytes after six months of fish oil supplementary intake, and that n-3 PUFA were effective in reducing ALP and liver fibrosis without altering the expression of circulating miR-122 in individuals with NAFLD.

Download Full-text